CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed Inc has showcased a strong financial foundation with a cash position of $38.9 million, providing a sufficient operational runway into mid-2026, which is crucial for supporting ongoing clinical trials. The recent Phase 2b extension results for Neflamapimod demonstrated statistically significant improvements in clinical measures, indicating the potential efficacy of the product candidate in treating dementia with Lewy bodies. Furthermore, the company's increasing investment in research and development, reflected by a rise in R&D expenses to $18.8 million, underscores its commitment to advancing its clinical programs and optimizing product formulations.
Bears say
CervoMed Inc faces significant financial risks as it remains a clinical-stage biotechnology company with no revenue-generating products, having incurred continuous losses since its inception. The disappointing results from the RewinD-LB trial, attributed to lower than expected plasma drug concentrations leading to underdosing, raise concerns regarding the efficacy of its product candidate, Neflamapimod. Additionally, the competitive landscape, characterized by both existing and emerging therapies targeting similar neurological indications, poses a threat to the company's potential market penetration and pricing strategies.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares